Navigation Links
Mayo Clinic study shows Parkinson's disease drug might work in cancer patients
Date:3/13/2008

ROCHESTER, Minn. -- A study published in the March 13 online issue of The Journal of Clinical Investigation shows that dopamine, a drug currently used to treat Parkinsons disease and other illnesses, also might work in cancer patients. The study, which was done in mouse and laboratory models, shows that dopamine could possibly prevent new blood vessels from growing and as a result, slow cancer progression.

Dopamine is a neurotransmitter in the brain that regulates movement and affects behavior. In its synthetic form, dopamine is used to treat heart attack victims, Parkinsons disease and pituitary tumors. But it wasnt known until now that dopamine worked by blocking the growth of new blood vessels (a process called angiogenesis).

Researchers now can test this concept in solid tumors where angiogenesis plays a critical role in the growth and progression of these cancers," says Sujit Basu, M.D., Ph.D., a Mayo Clinic scientist who conducted this study with Partha Sarathi Dasgupta, Ph.D., a scientist with the Chittaranjan National Cancer Institute (CNCI) in Calcutta, India.; and, Debanjan Chakroborty, Ph.D., a postdoctoral fellow in biochemistry at Mayo Clinic and CNCI.

Sometimes new drugs may not be the answer. We looked instead at a novel use for an established product and have found very promising results, Dr. Basu says.

The study has not been replicated in humans, but the results are encouraging, he says.

Dr. Basu has been studying the role of dopamine in cancer for years, and was credited with the initial discovery that dopamine can block new blood vessel growth. His current study is based on mouse and laboratory models of sarcoma -- a malignant tumor affecting soft tissues. The research is the first report that dopamine has a role in cancers use of endothelial progenitor cells to provide a supply line of nourishing blood, Dr. Basu says. These cells, a form of stem cells, are released by bone marrow into the blood system in response to the vascular endothelial growth factor-A (VEGF-A), which is a protein that is secreted by oxygen-deprived cancer cells. The endothelial progenitor cells then help form new blood vessels to feed the cancer.

Researchers discovered that dopamine stops the transfer of endothelial progenitor cells from the bone marrow into the circulatory system by binding to a specific receptor on the surface of the progenitor cells. This binding suppresses the activity of matrix metallopeptidase 9 (MMP-9), an enzyme that enables these cells to move out of bone marrow.

In their experiments, they found that treatment with dopamine significantly decreased mobilation of the progenitor cells from the bone marrow, and it also decreased MMP-9 expression.

This is the first time it has been shown that an important neurotransmitter like dopamine is regulating the mobilization of these progenitor cells from the bone marrow. This is very important and represents why these findings are so unique, Dr. Basu says.

Other authors include: Chandrani Sarkar, Ph.D., of both CNCI and Mayo Clinic; Uttio Roy Chowdhury, Ph.D., and Rathindranath Baral, Ph.D., both of CNCI.


'/>"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology: